Company AB Science

AB

FR0010557264

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 18:55:00 24/07/2026 +03			5-day change	1st Jan Change
0.5110 ^EUR	-2.48%		-16.50%	-66.73%

07-13	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
07-10	AB Science streamlines its portfolio and refocuses on two molecules

Business description: AB Science

AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Number of employees: 31

Sales by Activity: AB Science

Fiscal Period: December	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
Pharmaceuticals	1.61M	958K	970K	1.07M	1.17M

See all business segments

Geographical breakdown of sales: AB Science

Fiscal Period: December	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
Europe	-	-	-	-	955K
outside Europe	-	-	-	-	219K

See all geographic segments

Executive Committee: AB Science

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	07/07/2026
Laurent Guy DFI	Director of Finance/CFO	-	20/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	01/04/2018
Alexis Bernard PRN	Corporate Officer/Principal	-	-

See AB SCIENCE governance

Composition of the Board of Directors: AB Science

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	11/07/2001
Patrick Moussy BRD	Director/Board Member	-	20/09/2011
Cécile de Guillebon BRD	Director/Board Member	64	27/06/2021
Catherine Johnston-Roussillon BRD	Director/Board Member	68	27/06/2021
Guillemette Latscha BRD	Director/Board Member	-	27/06/2021
Stéphane Ledermann CHM	Chairman	-	07/07/2026

Composition of the Board of Directors

Shareholders: AB Science

Name	Stocks	%	Valuation
UBS Wealth Management SGIIC SA 0.004443 %	3,100	0.004443 %	3 137 €

Name	Stocks	%	Valuation
Friedland Gestion SAS 5.198 %	85,471	5.198 %	32 638 €

Name	Stocks	%	Valuation
Friedland Gestion SAS 4.167 %	64,103	4.167 %	20 081 €

List of AB SCIENCE shareholders

Company details: AB Science

AB Science SA

3, avenue George V

75008, Paris

+33 1 47 20 00 14

http://www.ab-science.com

Specialty & Advanced Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	-2.48%	-16.50%	-60.75%	-87.67%	46.55M
MERCK & CO., INC.	+0.45%	+2.80%	+55.83%	+20.48%	324B
MERCK KGAA	-0.07%	+2.09%	+22.76%	-11.68%	68.88B
HALOZYME THERAPEUTICS, INC.	+1.35%	+5.29%	+39.41%	+91.60%	9.72B
KYOWA KIRIN CO., LTD.	+0.93%	-1.38%	+1.71%	-4.10%	8.37B
SK BIOPHARMACEUTICALS CO., LTD.	+1.13%	+1.51%	-20.98%	-4.73%	4.32B
BETTA PHARMACEUTICALS CO., LTD.	-4.00%	+0.71%	-7.10%	+12.39%	3.62B
YUHAN CORPORATION	+4.90%	+5.79%	-39.25%	+19.34%	3.83B
SUPERNUS PHARMACEUTICALS, INC.	-2.10%	-3.83%	+40.64%	+53.74%	2.68B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-4.07%	-2.45%	-3.76%	-17.52%	2.04B
Average	-0.40%	-0.54%	+2.85%	+7.19%	42.72B
Weighted average by Cap.	+0.37%	+2.17%	+46.51%	+16.11%